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Abstract
Author Manuscript

Pioglitazone is an FDA-approved PPAR-γ agonist drug used to for treat diabetes, and it has
demonstrated neuroprotective effects in multiple models of central nervous system (CNS) injury.
Acute treatment after spinal cord injury (SCI) in rats is reported to suppress neuroinflammation,
rescue injured tissues, and improve locomotor recovery. In the current study, we additionally
assessed the protective efficacy of pioglitazone treatment on acute mitochondrial respiration, as
well as functional and anatomical recovery after contusion SCI in adult male C57BL/6 mice. Mice
received either vehicle or pioglitazone (10 mg/kg) at either 15 min or 3 hr after injury (75 kDyn at
T9) followed by a booster at 24 hr post-injury. At 25 hr, mitochondria were isolated from spinal
cord segments centered on the injury epicenters and assessed for their respiratory capacity. Results
showed significantly compromised mitochondrial respiration 25 hr following SCI, but pioglitazone
treatment that was initiated either at 15 min or 3 hr post-injury significantly maintained
mitochondrial respiration rates near sham levels. A second cohort of injured mice received
pioglitazone at 15 min post injury, then once a day for 5 days post-injury to assess locomotor
recovery and tissue sparing over 4 weeks. Compared to vehicle, pioglitazone treatment resulted in
significantly greater recovery of hind-limb function over time, as determined by serial locomotor
BMS assessments and both terminal BMS subscores and gridwalk performance. Such
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improvements correlated with significantly increased grey and white matter tissue sparing,
although pioglitazone treatment did not abrogate long-term injury-induced inflammatory
microglia/macrophage responses. In sum, pioglitazone significantly increased functional
neuroprotection that was associated with remarkable maintenance of acute mitochondrial
bioenergetics after traumatic SCI. This sets the stage for dose-response and delayed administration
studies to maximize pioglitazone’s efficacy for SCI while elucidating the precise role that
mitochondria play in governing its neuroprotection; the ultimate goal to develop novel therapeutics
that specifically target mitochondrial dysfunction.

Keywords
PPAR; mitoNEET; neuroprotection; bioenergetics; locomotor recovery
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INTRODUCTION
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There are approximately 17,000 new traumatic spinal cord injury (SCI) cases in the United
States each year yet, despite numerous clinical trials, there are currently no comprehensively
accepted therapies to treat the pathophysiology of acute traumatic SCI (Center, 2016;
Rabchevsky et al., 2011). The exception is methylprednisolone sodium succinate (MPSS),
the only clinically approved compound reported to show modest efficacy on certain
functional outcome measures when administered within the first 8 h after SCI (Bracken,
1990, 2001; Bracken et al., 1984; Bracken et al., 1992; Bracken et al., 1990; Bracken et al.,
1985; Bracken et al., 1997). Traumatic SCI is characterized by an initial mechanical insult
followed by a series of destructive pathophysiological cascades that disrupt a constellation
of biochemical and cellular signaling pathways (Hall and Springer, 2004; McEwen et al.,
2011). Mitochondrial dysfunction is thought to be one of the primary cause/effect
components of these secondary events since they are the principal energy producers for the
cell, as well as the main site for reactive oxygen/nitrogen species (ROS/RNS) formation
which initiate many cell death mechanisms (Finkel, 2001; Patel et al., 2012; Patel et al.,
2010; Sullivan et al., 2007; Sullivan et al., 2005; Yonutas et al., 2015). Accordingly, there is
emerging evidence that preventing mitochondrial dysfunction acutely with
pharmacotherapeutics following experimental neurotrauma results in significant
neuroprotection and functional recovery at later stages (Pandya et al., 2014; Patel et al.,
2012; Patel et al., 2010; Patel et al., 2014; Sauerbeck et al., 2011).
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Pioglitazone is an FDA approved treatment for type-2 diabetes and belongs to a class of
drugs called thiazolidinediones (TZDs), which are peroxisome proliferating activating
receptor (PPAR) agonists (Michalik et al., 2004; Michalik and Wahli, 1999; Sood et al.,
2000). The three isoforms of PPAR (PPRA-α, PPAR-β/δ, and PPAR-γ) are part of the
nuclear receptor superfamily and perform a wide array of tasks, such that their function has
not been systematically defined (Berger and Moller, 2002; Michalik and Wahli, 1999;
Yonutas and Sullivan, 2013). Nevertheless, it is widely accepted that PPAR activity plays a
critical role in lipid metabolism, modulates expression patterns of pro-inflamatory cytokines,
and increases expression of antioxidant proteins (Chen et al., 2007; Frazier-Wood et al.,
2013; Kapadia et al., 2008; Martin et al., 2012; Sood et al., 2003; Yi et al., 2008). The TZDs
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which bind PPAR-γ are particularly germane to SCI therapeutics, notably pioglitazone.
Pioglitazone can rapidly cross the blood-brain barrier (Berger and Moller, 2002) and has
demonstrated more robust neuroprotection than other TZDs such as rosiglitazone which has
higher binding affinity for PPAR-γ (Kapadia et al., 2008; Thal et al., 2011). This may be
due to emerging evidence that pioglitazone’s therapeutic effects may also depend on PPARindependent mechanisms that ameliorate mitochondrial dysfunction and which stem from its
interactions with the mitoNEET, an iron-sulfur domain-containing protein (Colca et al.,
2004).
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mitoNEET is a protein localized in the brain, liver and skeletal muscles of rodents (Colca et
al., 2004). This finding came long after the discovery that pioglitazone had a binding affinity
for the mitochondrial membrane. After further investigation, it was determined that this
binding was mediated through a new m-17 kDa protein which was later termed mitoNEET
(Colca et al., 2004). At the time of its discovery, mitoNEET was proposed to be a pivotal
protein for mitochondrial metabolism which had the potential of being modulated by
pioglitazone. Since its initial discovery, the exact role of mitoNEET in the cell remains
uncertain. However, a handful of groups have studied mitoNEET’s protein dynamics and
suggested one possible role is to be a shuttle protein for the mitochondria (Conlan et al.,
2009; Hou et al., 2007; Lin et al., 2007; Paddock et al., 2007). Pioglitazone binding can then
inhibit the transfer of [2Fe-2S] clusters making mitoNEET unable to dimerize and perform
its necessary task. Additionally, through the use of mitoNEET knockout mice, it was shown
that mitochondria without mitoNEET have a decreased oxidative capacity which suggests
that this iron-containing protein may be pivotal in controlling the rate of mitochondrial
respiration (Geldenhuys et al., 2011; Kusminski et al., 2012; Pedada et al., 2014; Wiley et
al., 2007). Finally, a recent study has highlighted that mitoNEET is a redox-sensitive protein
and can be reduced by biological thiols such as gluthathione (GSH), reversing the effect of
mitoNEET oxidation (Landry and Ding, 2014) in accordance that GSH precursors can
reverse mitochondrial dysfunction and afford neuroprotection following CNS injuries
(Pandya et al., 2014; Patel et al., 2014).
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Pioglitazone has been shown to reduce neuroinflammation, restore mitochondrial
homeostasis, spare neurons, and promote functional recovery following traumatic brain
injury (TBI) (Liu et al., 2016; Sauerbeck et al., 2011; Thal et al., 2011). However, much of
the protection appears to be independent of PPAR, given the concentrations used and the
incomplete reversal of protection in the presence of PPAR antagonists, again indicating a
potential role for mitoNEET in mediating pioglitazone neuroprotection. Despite its use in
TBI, pioglitazone has a limited but promising history of experimental therapeutic application
for SCI, studied exclusively in rats (McTigue et al., 2007; Park et al., 2007). Furthermore, its
effects on mitochondrial bioenergetics after SCI remain uncharacterized. While pioglitazone
has been shown to preserve mitochondrial function following TBI in mice (Sauerbeck et al.,
2011), it is not known if pioglitazone elicits similar outcomes following SCI. Accordingly,
in the current study we assessed the protective efficacy of pioglitazone treatment on
mitochondrial bioenergetics acutely and long-term functional recovery and tissue sparing
following contusion SCI in mice.
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MATERIALS AND METHODS
Animals
Adult male C57BL/6 mice (n = 64) (Jackson Laboratories, Bar Harbor, Maine) were housed
in a vivarium at 25°C under a 12 hour light/dark cycle and were allowed access to food and
water ad libidum. All experimental procedures occurred during the light cycle. All
procedures were approved by and in accordance with the University of Kentucky
Institutional Animal Care and Use Committee.
Spinal Cord Injury Surgery and Treatments
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Before surgery, animals were deeply anesthetized via ketamine (150 mg/kg) and xylazine
(10 mg/kg) injection (i.p.). The surgical site was shaved and disinfected with isopropyl
alcohol and betadine. A small incision was made on the dorsal surface, and the muscle and
subcutaneous tissue overlaying the thoracic spine were retracted. A T9 laminectomy was
performed to expose the mid-thoracic spinal cord. Severe contusions were produced using
the Infinite Horizons impactor device (75 kdyn; Precision Systems and Instrumentation,
LLC, Lexington KY, USA) as we have described previously (Zhang et al., 2015b). The hit
parameters (mean ± SD) for mice included in final analyses were equivalent between vehicle
(n=19) and pioglitazone (n=29) treated injury cohorts for impact force [vehicle group (78.26
kdyn ± 2.56) vs pioglitazone group (78.48 kdyn ± 3.0)], cord displacement [vehicle group
(586.2 μm ± 91.74) vs pioglitazone group (559.3 μm ± 80.53)], and velocity at impact
[vehicle group (120.9 m/s ± 2.77) vs pioglitazone group (122.0 m/s ± 2.26)]. Any injured
animals with abnormalities in the force vs time curve, which are indicative of bone hits or
instability of the spinal cord, were excluded from analysis. For biochemical assessment of
mitochondrial integrity, sham mice (n = 7) received laminectomy only and displayed normal
hind-limb function post-surgery. The wound was closed with monofilament suturing of the
muscle and skin incisions. Afterwards, animals were returned to their home cage placed a
heating pad and administered injections (s.c.) of Buprenorphine SR (0.1 mg/kg, Reckitt
Benckisser Pharmaceuticals Inc., Richmond, VA) and Baytril (2.5 ml/kg, mixed with 2 ml
Sterile Saline), then allowed to regain consciousness.

Author Manuscript

Injured mice being assessed for acute mitochondrial respiration (n=27 total) received an
injection (i.p) of either pioglitazone (10 mg/kg, dissolved in DMSO at 3mg/ml) at 15 min (n
= 9) or 3 hr (n = 10), versus vehicle (DMSO) 15 min after injury (n = 7), and they also
received a booster of pioglitazone or DMSO at 24 hr post-injury, one hour prior to tissue
harvesting. Due to postsurgical complications, one mouse died prior to acute biochemical
assessments. Long-term behavioral experiments were carried out using two independent
cohorts (n=30 total). Injured mice received an injection (i.p) of either 10mg/kg pioglitazone
(n = 10) or 100% DMSO (n = 12) 15 min after injury, and then daily injections (i.p.) of
either pioglitazone or DMSO for 5 days post-injury, followed by injection (s.c.) of Baytril
(2.5 ml/kg, mixed with 1 ml sterile saline). Manual bladder expression was performed twice
daily on injured mice. Data for 8 injured mice are not presented because they were either
excluded due to post-injury complications or died. Specifically, three mice were euthanized
due to abnormal contusions, one due to severe bladder infection, two due to autophagia, and
one mouse died during long-term behavioral experiments for unknown reasons.
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Mitochondria from sham and injured spinal cords were isolated by modifying our previously
reported method (Patel et al., 2014; Patel et al., 2009). At 24 hr post-injury, animals were
decapitated and a 0.5 cm thoraco-lumbar spinal cord segment centered on injury site was
rapidly dissected from all injured as well as naive mice and homogenized in an ice-cold
dissecting plate containing isolation buffer with 1 mM EGTA (215 mM mannitol, 75 mM
sucrose, 0.1% BSA, 20 mM HEPES, 1 mM EGTA, and pH adjusted to 7.2 with KOH). The
homogenate was centrifuged at 1400 ×g for 3 min at 4 °C. Supernatant was transferred to a
new 2 ml tube (S1, containing mitochondria and cytosol). The pellet was resuspended in 2
ml isolation buffer and centrifuged at 1400 ×g for 3 min and this supernatant was transferred
to a new tube (S1′, containing mitochondria and cytosol) and the pellet was discarded. Both
supernatant fractions (S1 & S1′) were then topped off with isolation buffer and centrifuged
at 13,000 ×g for 10 min. The resultant two pellets were pooled and resuspended in 500 μl
isolation buffer (with EGTA) and burst in a nitrogen cell disruption bomb at 4 °C for 10 min
at 1200 psi to release synaptic mitochondria from synaptosomes. Resultant differential
mitochondrial suspension was then centrifuged at 10,000 ×g for 10 min. Pellets were resuspended in ~20ul of isolation buffer (without EGTA). All samples were kept on ice
throughout the isolation process. The protein concentrations were determined using BCA
protein assay kit (Thermo Scientific, Rockford, IL) by measuring absorbance at 560 nm with
a Biotek Synergy HT plate reader (Winooski, Vermont). Note: isolation and measurements
of OCRs were completed as quickly as possible after dissecting the tissues (within 5–6 hrs).
Assessment of Mitochondrial Respiration

Author Manuscript
Author Manuscript

Respiration of mitochondrial samples was measured in terms of mitochondrial oxygen
consumption rate (OCR) using a Seahorse Bioscience XF24 Extracellular Flux Analyzer as
described previously with slight modifications (Sauerbeck et al., 2011). Briefly, 24 hr prior
to each experiment, a 24 well dual-analyzer sensor cartridge (Seahorse Bioscience) was
incubated with 1 ml/well of XF Calibrant solution (Seahorse Bioscience) at 37 °C in a CO2free incubator (Seahorse Bioscience). On the days of experimentation, either A) pyruvate
plus malate plus ADP, B) oligomycin, C) FCCP, or D) rotenone plus succinate were added in
ports A–D, respectively, in the Seahorse Flux Pak cartridges to yield final concentrations of
5 mM (pyruvate), 2.5 mM (malate), 1 mM (ADP), 1 μg/ml (oligomycin), 3 μM (FCCP), 100
nM (rotenone), and 10 mM (succinate) and placed into the Seahorse XF24 Flux Analyzer for
automated calibration. During the sensor calibration, 50 μl volume of respiration buffer
containing 5 μg of mitochondrial protein was added to each well of XF24 V7 cell culture
microplates and centrifuged at 2000 rpm for 4 min at 4 °C. This was followed by addition of
450 μl of respiration buffer (125 mM KCl, 2 mM MgCl2, 2.5 mM KH2PO4, 20 mM HEPES
and 0.1% BSA, pH 7.2) at 37 °C (gently added to each well) to make the final assay volume
500 μl per well. Plates were immediately placed into the calibrated Seahorse XF24 Flux
Analyzer for assessment of mitochondrial OCR in the presence of substrates and inhibitors
in respective ports. The OCR data were analyzed using Excel software package (Microsoft),
point by point rates were generated using the AKOS algorithm written by AKOS Gerencser
for Seahorse Bioscience. For State III and State V—Complex I, the “middle point” (average)
of OCR was generated from 4 time-dependent point-by-point rates for each well sample.
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Then, three independent middle points were averaged for each sample to generate n = 1 per
sample.
Behavioral Analyses

Author Manuscript

Recovery of hind limb motor function was assessed as previously described using the Basso
Mouse Scale (BMS) (Basso et al., 2006; Zhang et al., 2015b). Mice were assessed in an
open field apparatus pre-surgically and at 1, 3, 7, 14, 21, and 28 days post-injury (DPI) by
two trained observers. Each hind limb was rated independently for movement coordination,
and trunk stability, and then averaged to generate a single score on a scale of 0–9. Subscores
were also assigned based on frequency of plantar stepping, paw placement, coordination,
trunk stability, and tail position. Further assessments of hindlimb function were conducted
using the gridwalk test (Cummings et al., 2007; Zhang et al., 2015a). Briefly, the gridwalk
apparatus consists of an elevated horizontal ladder (92 cm × 16.5 cm), with rungs (4mm in
diameter) spaced 1cm apart, and with a covered black goal box at one end. A high speed
camera (Basler scA640) was placed 32cm under the middle of the ladder. Animals were
trained on the apparatus prior to surgery. At 28 DPI, mice were acclimated to the dark box
for three minutes, then removed and placed at the opposite, uncovered end of the apparatus
and recorded as they crossed the length of the ladder back into the dark box. At least three
passes were recorded per animal. Each animal’s best pass was chosen for analysis, as
determined by overall coordination and uninterrupted movement. The total number of
missed steps across 30 rungs was then calculated for each animal’s best pass. A missed step
was counted when an animals’ hindlimb slipped below the horizontal plane of the rungs.
Spinal Cord Tissue Processing

Author Manuscript

Tissues were processed according to our previously established methods (Zhang et al.,
2015b). Briefly, mice were anesthetized via ketamine (150 mg/kg) and xylazine (10 mg/kg)
injection (i.p.). The chest cavity was then opened and animals were perfused transcardially
with 0.1M phosphate-buffered saline (PBS, 7.4 pH) followed by 4% paraformaldehyde
(PFA) in 0.1M PBS. A 1cm segment of spinal cord centered on the injury site was dissected
and post-fixed in PFA for 2 hours before being washed overnight in 0.2M phosphate buffer
(7.4 pH). Tissues were cryoprotected in 20% sucrose in 0.1M phosphate buffer saline at 4°C
until the cords sank (3–5 days). Spinal cords were then trimmed to a 6mm segment centered
on the injury epicenter and evenly distributed by experimental group into blocks containing
optimal cutting temperature (OCT) compound. The blocks were rapidly frozen then stored at
−80°C. A total of 6 mm spinal cord segment was serially cryosectioned at 10 μm thick
coronal sections and every section was collected for a total of 10 slide series, with 6 slides in
each series. Therefore, adjacent sections on a slide were separated by 100 μm.

Author Manuscript

Histology
A modified Eriochrome Cyanine (EC) staining protocol for myelin was used to differentiate
between damaged tissue and spared white and grey matter (Rabchevsky et al., 2002; Zhang
et al., 2015a). Briefly, slides were hydrated in dH20, submerged in acetone for 2 minutes,
rehydrated in dH20, and then exposed to serial dilutions of decreasing concentration of
EtOH before being incubated in EC for 30 minutes at room temperature. Excess stain was
removed by dH20 washes and slides were differentiated in 0.3% Ammonium Hydroxide. All
Exp Neurol. Author manuscript; available in PMC 2018 July 01.
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histological analyses were conducted blindly with respect to treatment condition using a
Nikon microscope (Nikon Corporation, Tokyo, Japan) and Scion imaging analysis software
(Scion Corporation, Frederick, MD, USA). Identification of intact white and grey matter was
based on positive myelin staining as well as comparisons to normal cytoarchitecture. The
cross-sectional area of lesion and spared tissues were quantified at 200μm intervals adjacent
to the injury epicenter using the Cavalieri method (Rabchevsky et al., 2002), for a total of 17
sections per animal.
Immunohistochemistry

Author Manuscript

Prior to staining, frozen slide-mounted spinal cord sections were thawed for 1 hr at 37°C and
rinsed with 0.1M PBS 3 × 5 min. Slides were then incubated at room temperature for 1hr in
blocking buffer (0.1M PBS containing 1% bovine serum albumin, Fisher Scientific, Cat#
BP1605), 0.1% Triton X-100 (Sigma-Aldrich, Cat# X-100), 0.1% fish gelatin (SigmaAldrich, Cat# G7765), and 5% normal goat (SigmaeAldrich, Cat# G9203). Double
immunolabeling for ionized calcium-binding adapter molecule 1 (IBA-1), to evaluate
microglia/brain macrophages, and glial fibrillary acidic protein (GFAP), to visualize the
astrocytic scar, was performed by incubating slides in chicken anti-GFAP (10ug/ml; Aves,
Cat# GFAP) and rabbit anti-IBA-1 (1ug/ml; Wako, Cat# 019-19741) primary antibodies
overnight at 4°C in blocking buffer. On the second day, slides were rinsed in 0.1M PBS
followed by a 1 hr incubation at room temperature of goat anti-chicken Alexa Flour (AF)
488 (2ug/ml; Life Technologies A-11039) and goat anti-rabbit AF546 (2ug/ml; Life
Technologies A-11010) secondary antibodies in blocking buffer. Slides were then rinsed in
0.1M PBS and then were incubated in DAPI (1:95 in 0.1M PBS; Invitrogen D1306) for 30
min, then rinsed and coverslipped with Immu-Mount (Thermo-Scientific, Waltham, MA).
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Microscopy and Densitometry
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Fluorescent images were captured using a C2+ laser scanning confocal microscope (Nikon
Instruments Inc., Melville, NY). For each animal, images were taken at the SCI epicenter
(determined by lesion volume estimates and visually confirmed by GFAP staining) as well
as 0.6mm and 1.2mm, rostral and caudal to the epicenter. A montaged maximum-intensity
projection image, consisting of 9 adjacent z-stacks, was generated for each tissue section.
When necessary, laser powers were adjusted to capture the full fluorescent intensity range of
lightly stained sections. To quantify the proportional area of activated microglia/
macrophages, threshold-based analysis of IBA-1 immunoreactivity was performed as
described previously with modifications (Donnelly et al., 2009). Captured RGB images were
opened in the MetaMorph analysis program (Molecular Devices, Sunnyvale, CA) and the
perimeter of each section was digitally outlined referencing the cytoarchitecture revealed by
GFAP and IBA-1 staining. Next, the AF546 channel was isolated and a threshold selected
which identified positive IBA-1 staining above background. For each tissue section, the
density of IBA-1 staining was calculated as the ratio of immunoreactive area/region of
interest area (entire cross section).
Statistical Analyses
All statistical analyses were performed using GraphPad Prism 6 (GraphPad Software, Inc.,
La Jolla, CA). For mitochondrial bioenergetics, differences between groups were
Exp Neurol. Author manuscript; available in PMC 2018 July 01.
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investigated via analysis of variance (ANOVA). Two-way ANOVA were run to analyze
differences in tissue morphology across spinal cord levels and to determine changes in BMS
data over time. The 28-day BMS subscores and histological assessments were analyzed by
one-tailed unpaired Student’s t-tests. Correlational analyses were run between histological
measures and terminal BMS. When warranted, post-hoc analyses (Bonferroni) were
performed. Significance was identified at p<0.05.

RESULTS
Effects of pioglitazone on mitochondrial bioenergetics

Author Manuscript

Quantification of mitochondrial respiration in terms of OCR demonstrated that SCI result in
significantly decreased State III OCR (F(3,28)=14.16, p<0.0001) and State V-I OCR
(F(3,28)=16.10, p<0.0001) in all injured groups compared to Sham (Figure 1). Post hoc
analysis showed a significant (p<0.05) decrease in all State III and State V-I in vehicle
treated animals compared to Sham. Conversely, treatment with pioglitazone at 15 min and 3
hr post-injury significantly maintained State III and State V-I OCRs. However, State III and
State V-I OCRs remained significantly lower than Sham (Figure 1).
Effects of pioglitazone on functional recovery
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We next assessed the effects of pioglitazone on long-term functional recovery. The data
revealed that while both vehicle-and pioglitazone-treated animals demonstrated severe
hindlimb paralysis following injury, pioglitazone-treated mice showed improved hindlimb
function as early as 7 DPI, (Figure 2A). A two-way repeated measures ANOVA revealed
main effects of time (F(6,120)=296.04, p<0.0001) and treatment condition (F(1,20)=7.90,
p<0.05). Throughout post-injury assessments pioglitazone-treated mice outperformed
vehicle-treated animals, precluding an interaction of the variables (F(5,100)=1.030, p=0.4).
Furthermore, pioglitazone-treated animals outperformed vehicle-treated mice on multiple
terminal assessments of fine locomotor skills. Specifically, Student’s t-tests revealed that
pioglitazone treatment was associated with substantially higher terminal BMS subscores
(p<0.01, Figure 2B). Specifically, differences in terminal BMS subscores are associated with
higher number of animals with plantar stepping and coordinated walking pattern, better paw
position and tail position above the ground compared to vehicle-treatment, which was
revealed in significantly improved performance on the gridwalk assessment (p<0.05, Figure
2C).
Effects of pioglitazone on tissue sparing
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Histological assessment of spinal cord sections revealed marked tissue sparing following
pioglitazone treatment compared to vehicle, as shown in representative photomicrographs
(Figure 3A). Analysis of cross-sectional areas revealed increased white matter sparing in
pioglitazone-treated group compared to vehicle, particularly in the sections rostral and
penumbral to the epicenter (Figure 3B). A two-way ANOVA revealed a main effect of
treatment (F(1,340)=16.86, p<0.0001) and spinal level (F(16,340)=47.32, p<0.0001).
Similarly, quantification of gray matter area showed increased spared gray matter sparing
with pioglitazone treatment, and sparing was most evident in the cross-sections rostral to the
epicenter were grey matter was effectively abolished (Figure 3C). A two-way ANOVA
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revealed main effects of treatment (F(1,340)=5.607, p<0.05) and spinal level
(F(16,340)=10.58, p<0.0001). Pioglitazone treatment also resulted in reduced lesioned tissue
compared to vehicle-treated animals across nearly all of the cord (Figure 3D). Accordingly,
a two-way ANOVA revealed a main effect of treatment (F(1,340)=11.76, p<0.001) and
spinal level (F(16,340)=76.77, p<0.0001). Analyses across the entire rostral-caudal extent of
injury (3.2 mm of spinal cord) showed that the pioglitazone-treated group had significantly
(p<0.05) less lesion volume, which corresponded to significantly (p<0.05) greater white and
grey matter volumes (Figure 3E). Correlational analyses indicate that these anatomical
measures significantly correlated with functional outcome measures (Figure 4). Collectively,
these results show that pioglitazone treatment significantly reduces secondary injury
evidenced by increased spared tissue and decreased lesion volume associated with improved
functional recovery, specifically hindlimb-forelimb coordination.

Author Manuscript

Effects of pioglitazone on microglia/macrophage responses
Because pioglitazone may block PPAR on microglia/macrophages, we also examined the
effects of pioglitazone treatment on the inflammatory response to SCI. Despite differences in
spared tissues, demarcated by GFAP+ astroglial scars, IBA-1+ microglia/macrophage
responses to SCI appeared the same in vehicle- vs. pioglitazone-treated mice at 28 DPI
(Figure 5A). Such responses were concentrated at the injury epicenter and tapered off at
distal regions, and there was a trend for reduced IBA-1+ densities after pioglitazone
treatment. However, while a two-way ANOVA revealed a significant main effect of spinal
level (F(4,100)=46.45, p<0.001), there was no treatment effect (F(1,100)=2.321, p>0.05) or
treatment × spinal level interaction (F(4,100)=0.2667, p>0.05) (Figure 5B).
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Our results demonstrate for the first time that pioglitazone modulates mitochondrial function
after SCI and this is associated with improved recovery and tissue sparing. Dosage as well as
timings and duration of pioglitazone administration were based on our previous reports in a
TBI model (Sauerbeck et al., 2011). As we hypothesized, by maintaining mitochondrial
function acutely after SCI, daily treatment with pioglitazone resulted in increased tissue
sparing and functional recovery at later stages. Furthermore, pioglitazone-treated animals
displayed significantly improved hindlimb motor recovery throughout the post-injury period
and at terminal assessments, which correlated with greater tissue sparing. These behavioral
and morphological data are consistent with previous investigations of pioglitazone treatment
for SCI in rats (McTigue et al., 2007; Park et al., 2007), and here we report for the first time
that pioglitazone treatment improves gridwalk performance in injured mice. This is an
important and refined behavioral consideration, as the gridwalk task discriminates between
animals which display the same stepping frequency during open-field assessment
(Cummings et al., 2007). Our seminal finding, however, is that similar treatment in SCI mice
significantly protected acute mitochondrial function, both after immediate and 3 hr delayed
administrations. Moreover, the tissue sparing afforded by pioglitazone was not associated
with decreased levels of microgliosis, again in accordance with findings in a rat SCI model
(McTigue et al., 2007).
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Rescuing mitochondrial bioenergetics is linked to improved functional neuroprotection
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A growing body of data indicates that preserving mitochondrial bioenergetics following
CNS injury is a powerful therapeutic strategy for reducing tissue damage and attenuating
locomotor deficits. Multiple interventions which target the mitochondria have shown
promise, including administration of mitochondrial uncouplers (Patel et al., 2009),
alternative biofuels (Patel et al., 2012; Patel et al., 2010), and glutathione precursors (Pandya
et al., 2014; Patel et al., 2014). We have previously demonstrated that pioglitazone maintains
mitochondrial integrity following TBI (Sauerbeck et al., 2011) and the current study extends
these findings, demonstrating that pioglitazone preserves mitochondrial function after SCI as
well. Likewise, improving mitochondrial function was associated with increased tissue
sparing and improved behavioral performance.
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While a number of SCI therapeutics have directly targeted downstream pathophysiological
cascades such as oxidative damage, the present study and our previous data suggest that a
more promising approach for clinical translation may be targeting upstream processes,
specifically mitochondrial respiration. CNS trauma causes an influx of intracellular Ca2+,
which increases Ca2+ absorption by mitochondria (Sullivan et al., 2005) and this Ca2+
sequestering increases production of reactive oxygen species (ROS) (Dugan et al., 1995).
Free radical damage via lipid peroxidation is known to contribute significantly to the
propagation of tissue damage after injury (Anderson and Hall, 1993; Hall, 1991; Hall and
Braughler, 1993; Springer et al., 1997). These effects are compounded since oxidative stress
instigates pro-inflammatory responses (Christman et al., 2000). Critically, we have
previously demonstrated that maintaining mitochondrial bioenergetics reduces oxidative
stress following contusion SCI (Patel et al., 2009).
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We have reported that significant mitochondrial dysfunction occurs as early as 6 hr post-SCI
in rats (Sullivan et al., 2007), indicating a clinically relevant window of opportunity to
rescue mitochondrial dysfunction after injury. This may help to explain, in part, why there
were no changes in OCR values after 15 min vs 3 hr post-injury administration of
pioglitazone. Irrespective of targeting mitochondrial bioenergetics, antagonism of PPAR-γ
by itself can reduce pro-inflammatory activities (Drew et al., 2006). Accordingly, low-dose
pioglitazone treatment after SCI in rats (1.5 mg/kg i.p.; four doses at 5 min and 12, 24, and
48 h) significantly reduced the number of activated microglia at 7 days following injury
(Park et al., 2007). In contrast, dosing throughout the first week after SCI (10 mg/kg i.p. at
15 min post-SCI, then every 12 hr for 7 days) did not reduce macrophage accumulation in
the lesion at 7 DPI (McTigue et al., 2007). Consistent with the latter results, we detected no
significant long-term changes in microglia/macrophage accumulation after pioglitazone
treatment (10 mg/kg i.p. at 15 min post-SCI, then daily for 5 days) (Figure 5). Notably, the
qualitative trends for reduced microglia/macrophage densities following pioglitazone
treatment likely reflects increased tissue sparing compared to vehicle-treated groups (Figure
3).
We have also shown, however, that in the context of TBI pioglitazone treatment reduces
microglial activation via PPAR-γ independent mechanisms. More specifically, delivery of a
PPAR-γ antagonist (T0070907) in conjunction with pioglitazone elicited similar reduction
in activated microglia as pioglitazone treatment alone (Sauerbeck et al., 2011). This could be
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due, in part, to reduced mitochondrial dysfunction and consequent tissue damage as a result
of pioglitazone treatment leading to a reduction in downstream inflammatory cascades.
Likewise, emerging evidence suggests that protective effects of pioglitazone following
experimental TBI in mice are not solely related to PPAR-γ-dependent mechanisms (Thal et
al., 2011). Although it has been established in TBI, it will be important to determine if the
results of the current study are, in fact, PPAR-γ independent.
Interactions between pioglitazone and mitoNEET
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Over a decade ago, pioglitazone was found to bind to a novel outer mitochondrial membrane
protein which was then termed “mitoNEET” (Colca et al., 2004). Evidence now suggests
that mitoNEET plays a critical role in energy homeostasis through regulating β-oxidation
rates by controlling iron transport into the inter-membrane matrix (Kusminski et al., 2012).
There are important differences between the effects of binding mitoNEET by pioglitazone,
compared with other PPAR-γ agonists. For instance, compared with pioglitazone,
rosiglitazone has a stronger binding affinity for PPAR-γ and a weaker affinity for
mitoNEET, yet has demonstrated less robust neuroprotection following CNS trauma (Berger
and Moller, 2002). Furthermore, data from our TBI experiments suggest that pioglitazone’s
ability to improve mitochondrial function may be due, in part, to its acute effects on
mitochondrial respiration (Sauerbeck et al., 2011). More specifically, we found that a single
injection of pioglitazone 15 min after TBI results in a non-significant trend towards
improved mitochondrial function when respiration was measured the next day. Conversely,
when an additional injection was given 1 hour prior to analyzing the injured tissue,
significant improvement in respiration was observed. Collectively, these data point towards
our working hypothesis that neuroprotective effects of pioglitazone are at least partially
independent of PPAR-γ activation and rely, instead, on direct modification of mitochondrial
integrity.
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Overall, while this study represents an independent replication of reports that pioglitazone
treatment following contusion SCI in rats improves long-term neuroprotection (McTigue et
al., 2007; Park et al., 2007), we further identified that pioglitazone treatment after contusion
SCI in mice significantly attenuates acute mitochondrial dysfunction. We also found
comparable maintenance of mitochondrial bioenergetics following both early and delayed
treatment, setting the stage for testing more delayed administration. Accordingly, ongoing
studies are assessing different dosages and clinically relevant therapeutic windows of
administration (3–6 hr post-injury) to potentially repurpose pioglitazone for neurotrauma
and/or develop novel therapeutics that target mitochondrial dysfunction. In addition to
planned stereological studies to evaluate neuroprotection, comprehensive assessments of
neuroinflammatory markers and microglia/macrophage phenotypes will also help to
elucidate the mechanisms by which pioglitazone confers both bioenergetics homeostasis and
tissue sparing.
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Highlights
•

Pioglitazone (Pio) maintains acute mitochondrial bioenergetics after spinal
cord injury.

•

Prolonged Pio treatment improves functional recovery following spinal cord
injury.

•

Improved functional recovery is correlated with increased tissue sparing.

•

Functional neuroprotection is not associated with reduced inflammatory
microgliosis.
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Figure 1.
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Effect of pioglitazone (Pio) treatment on mitochondrial respiration in terms of oxygen
consumption rate (OCR) 25 hrs following SCI. Compared to the sham group, SCI
significantly reduced mitochondrial OCR [State III, State V-I and State V-II)] for vehicle
treated animals. Conversely, Pio treatment significantly (p<0.05) preserved mitochondrial
OCR compared to vehicle. However, no differences were observed between groups when
comparing respiration measurements for State V (complex II) enzyme activity. Bars
represent means ± SEM, n =7–10 per group. *p<0.05 compared to Sham, #p<0.05 compared
to Vehicle.
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Effect of daily pioglitazone (Pio) treatment for five days post-injury (DPI) on multiple
measures of hindlimb functional recovery following SCI. A. Serial BMS testing before
injury through 28 days DPI showed that both vehicle-and Pio-treated animals displayed
severe hindlimb paralysis following injury; however, at all time-points post-injury, Piotreated mice scored higher than vehicle-treated animals. Pio-treated mice had greater
recovery of fine locomotor skills as assessed by terminal BMS subscores (B) and the
gridwalk test (C). Bars and symbols represent means ± SEM, n = 10–12 per group, *p<0.05
compared to vehicle; **p<0.01 compared to vehicle; #p<0.05 main effect of treatment.
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Effect of daily pioglitazone (Pio) treatment for five days post-injury (DPI) on
histopathological outcome measures following SCI. A. Representative photomicrographs
illustrate differences in tissue morphology between pioglitazone and vehicle-treated animals
at 28 days after injury. The Pio-treated group demonstrated increased tissue sparing
compared to vehicle treatment, particularly in the sections penumbral and/or rostral to the
lesion epicenter. Analysis of evenly spaced tissue sections showed that Pio-treated mice
displayed significant sparing of white (B) and grey (C) matter, and less injured tissue (D). E.
Quantification of tissue volumes across 3.2mm of injured spinal cord showed that Pio
treatment significantly decreased lesion volume while increasing spared white and grey
matter volumes. Bars and symbols represent means ± SEM, *p<0.05 compared to vehicle;
#p<0.05 main effect of treatment, n = 10–12 per group. Scale Bar = 200μm.
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Figure 4.

Correlation analyses: lesion volume and spared tissues versus terminal BMS scores. A.
There was a significant negative correlation between terminal BMS scores and lesion
volume, which corresponded to significant positive correlations between terminal BMS
scores and spared grey (B) and white (C) matter. There was also a notable group separation,
represented by encircled portions, indicating that pioglitazone (Pio) treatment showed
significant neuroprotection associated with higher BMS scores, as compared to vehicle
treatment. n = 10–12 per group.
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Figure 5.

Effect of pioglitazone (Pio) treatment on microglia/macrophage activation 4 weeks after
contusion SCI. A. Representative photomicrographs across injured spinal cord levels
illustrate similarities in activated IBA-1+ microglia/macrophage responses (red) in
pioglitazone-and vehicle-treated spinal cords, despite differences in spared tissue identifiable
by the GFAP+ glial scar (green). B. Photomicrographs of IBA-1+ immunoreactivity at the
injury epicenter are shown in the graph inset; the entire region of interest is outlined. Image
analysis throughout the cross-sectional area of tissue sections at the injury epicenter (Epi), as
well as 0.6 mm and 1.2 mm rostral and caudal, showed no significant differences (p>0.05)
across spinal levels. Symbols represent means ± SEM, n = 10–12 per group. Scale Bar =
200μm.
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